Morphosys Ag (MOR)

$18.8

-0.08

(-0.42%)

Market is closed - opens 7 PM, 15 Jul 2024

Performance

  • $18.59
    $18.91
    $18.80
    downward going graph

    1.12%

    Downside

    Day's Volatility :1.69%

    Upside

    0.58%

    downward going graph
  • $4.18
    $19.50
    $18.80
    downward going graph

    77.77%

    Downside

    52 Weeks Volatility :78.56%

    Upside

    3.59%

    downward going graph

Returns

PeriodMorphosys Ag
3 Months
4.33%
6 Months
74.56%
1 Year
148.68%
3 Years
1.95%

Highlights

Market Capitalization
2.8B
Book Value
- $6.96
Earnings Per Share (EPS)
-1.49
Wall Street Target Price
15.5
Profit Margin
-190.61%
Operating Margin TTM
-960.15%
Return On Assets TTM
-13.84%
Return On Equity TTM
-183.8%
Revenue TTM
241.5M
Revenue Per Share TTM
1.72
Quarterly Revenue Growth YOY
13.100000000000001%
Gross Profit TTM
229.6M
EBITDA
-444.9M
Diluted Eps TTM
-1.49
Quarterly Earnings Growth YOY
-0.87
EPS Estimate Current Year
-4.59
EPS Estimate Next Year
-1.91
EPS Estimate Current Quarter
-1.29
EPS Estimate Next Quarter
-0.82

Analyst Recommendation

Hold
    43%Buy
    56%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Morphosys Ag(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
8
10
Hold
9
8
6
Sell
00
00
2

Analyst Forecast

What analysts predicted

Downside of 17.55%

Current $18.80
Target $15.50

Company Financials

FY18Y/Y Change
Revenue
87.5M
↑ 14.45%
Net Income
-64.3M
↓ 19.55%
Net Profit Margin
-73.48%
↑ 31.06%
FY19Y/Y Change
Revenue
80.4M
↓ 6.13%
Net Income
-115.4M
↑ 83.39%
Net Profit Margin
-143.56%
↓ 70.08%
FY20Y/Y Change
Revenue
403.1M
↑ 356.69%
Net Income
120.4M
↓ 195.03%
Net Profit Margin
29.87%
↑ 173.43%
FY21Y/Y Change
Revenue
203.4M
↓ 45.19%
Net Income
-582.7M
↓ 625.59%
Net Profit Margin
-286.47%
↓ 316.34%
FY22Y/Y Change
Revenue
298.1M
↑ 54.94%
Net Income
-161.8M
↓ 70.64%
Net Profit Margin
-54.29%
↑ 232.18%
FY23Y/Y Change
Revenue
238.3M
↓ 14.37%
Net Income
-189.7M
↑ 25.6%
Net Profit Margin
-79.63%
↓ 25.34%
Q4 FY22Q/Q Change
Revenue
87.5M
↓ 14.66%
Net Income
352.9M
↓ 368.06%
Net Profit Margin
403.4%
↑ 531.82%
Q1 FY23Q/Q Change
Revenue
68.0M
↓ 23.69%
Net Income
-47.9M
↓ 113.32%
Net Profit Margin
-70.42%
↓ 473.82%
Q2 FY23Q/Q Change
Revenue
58.0M
↓ 14.69%
Net Income
-80.7M
↑ 68.54%
Net Profit Margin
-139.13%
↓ 68.71%
Q3 FY23Q/Q Change
Revenue
63.8M
↑ 20.0%
Net Income
-119.6M
↑ 61.69%
Net Profit Margin
-187.46%
↓ 48.33%
Q4 FY23Q/Q Change
Revenue
59.1M
↓ 7.4%
Net Income
48.3M
↓ 140.36%
Net Profit Margin
81.7%
↑ 269.16%
Q1 FY24Q/Q Change
Revenue
27.5M
↓ 53.38%
Net Income
-315.0M
↓ 752.56%
Net Profit Margin
-1.1K%
↓ 1225.37%
FY18Y/Y Change
Total Assets
616.4M
↑ 29.7%
Total Liabilities
57.6M
↓ 11.17%
FY19Y/Y Change
Total Assets
556.1M
↓ 7.86%
Total Liabilities
114.0M
↑ 101.9%
FY20Y/Y Change
Total Assets
2.0B
↑ 234.28%
Total Liabilities
1.3B
↑ 920.46%
FY21Y/Y Change
Total Assets
2.9B
↑ 54.04%
Total Liabilities
2.6B
↑ 122.64%
FY22Y/Y Change
Total Assets
2.6B
↓ 6.23%
Total Liabilities
2.4B
↓ 3.11%
FY23Y/Y Change
Total Assets
2.0B
↓ 15.46%
Total Liabilities
2.0B
↓ 11.71%
Q4 FY22Q/Q Change
Total Assets
2.6B
↓ 15.87%
Total Liabilities
2.4B
↓ 23.7%
Q1 FY23Q/Q Change
Total Assets
2.4B
↓ 6.98%
Total Liabilities
2.3B
↓ 4.78%
Q2 FY23Q/Q Change
Total Assets
2.3B
↓ 3.9%
Total Liabilities
2.3B
↓ 1.02%
Q3 FY23Q/Q Change
Total Assets
2.1B
↓ 1.94%
Total Liabilities
2.2B
↑ 2.71%
Q4 FY23Q/Q Change
Total Assets
2.0B
↓ 3.55%
Total Liabilities
2.0B
↓ 8.8%
Q1 FY24Q/Q Change
Total Assets
1.8B
↓ 9.61%
Total Liabilities
2.1B
↑ 5.86%
FY18Y/Y Change
Operating Cash Flow
-38.1M
↓ 13.46%
Investing Cash Flow
-203.4M
↓ 639.74%
Financing Cash Flow
205.3M
↑ 2095.57%
FY19Y/Y Change
Operating Cash Flow
-89.8M
↑ 140.88%
Investing Cash Flow
89.0M
↓ 144.72%
Financing Cash Flow
395.7K
↓ 99.8%
FY20Y/Y Change
Operating Cash Flow
43.4M
↓ 144.01%
Investing Cash Flow
-1.1B
↓ 1206.67%
Financing Cash Flow
1.1B
↑ 256719.36%
FY21Y/Y Change
Operating Cash Flow
-545.2M
↓ 1465.04%
Investing Cash Flow
-941.1M
↓ 5.53%
Financing Cash Flow
1.5B
↑ 45.83%
FY22Y/Y Change
Operating Cash Flow
-392.8M
↓ 23.83%
Investing Cash Flow
369.6M
↓ 141.52%
Financing Cash Flow
333.6M
↓ 76.46%
Q4 FY22Q/Q Change
Operating Cash Flow
-112.8M
↑ 382.81%
Investing Cash Flow
79.7M
↑ 31.58%
Financing Cash Flow
4.3M
↓ 98.64%
Q1 FY23Q/Q Change
Operating Cash Flow
-77.7M
↓ 32.37%
Investing Cash Flow
25.4M
↓ 68.77%
Financing Cash Flow
-49.4M
↓ 1234.55%
Q2 FY23Q/Q Change
Operating Cash Flow
-137.4M
↑ 76.83%
Investing Cash Flow
25.4M
↑ 0.0%
Financing Cash Flow
-5.1M
↓ 89.69%
Q3 FY23Q/Q Change
Operating Cash Flow
-33.7M
↓ 73.26%
Investing Cash Flow
39.4M
↑ 69.38%
Financing Cash Flow
-1.7M
↓ 63.36%

Technicals Summary

Sell

Neutral

Buy

Morphosys Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Glazer Capital, LLC

    0.96%
  • Balyasny Asset Management LLC

    0.87%
  • UBS Group AG

    0.78%
  • BlackRock Inc

    0.68%
  • Carlson Capital LP

    0.63%
  • TANG CAPITAL MANAGEMENT LLC

    0.53%

Company Information

MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.

Organization
Morphosys Ag
Employees
464
CEO
Dr. Jean-Paul Kress M.D.
Industry
Health Technology

FAQs